Clinical Trial Update: Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the effect of thiethylperazine (TEP) on amyloid beta drainage in early-to-mild Alzheimer’s disease; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• thiethylperazine (thiethylperazine)

Snippet

Sponsor: Immungenetics AG | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED